middle.news

How EMVision’s $3.8M Rebate and Overseas Approval Could Accelerate Stroke Tech

8:32am on Monday 16th of March, 2026 AEDT Healthcare
Read Story

How EMVision’s $3.8M Rebate and Overseas Approval Could Accelerate Stroke Tech

8:32am on Monday 16th of March, 2026 AEDT
Key Points
  • Received $3.8 million R&D tax refund for FY2025
  • AusIndustry approved Advance Overseas Finding for overseas R&D costs
  • Eligible for 43.5% R&D tax rebate on overseas expenditures through 2027
  • Funding boost supports emu™ pivotal trial and market access activities
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Emvision Medical Devices (ASX:EMV)
OPEN ARTICLE